Last updated: February 24, 2026
What is the Drug with NDC 72241-0038?
NDC 72241-0038 corresponds to Xywav, a successor to Xyrem. It is a sodium oxybate-based medication approved by the FDA in July 2021 for treating narcolepsy with cataplexy and idiopathic hypersomnia. The drug is marketed by Jazz Pharmaceuticals.
Market Size and Usage Trends
Estimated Patient Population
- Narcolepsy with Cataplexy: Approximately 125,000 patients in the US.
- Idiopathic Hypersomnia: Estimated at 5,000 to 10,000 patients.
- Total Market Potential: 130,000 to 135,000 patients.
Usage Considerations
- Oral solution formulation enables outpatient and inpatient administration.
- Prescriber adoption remained gradual in 2022, with initial increasing prescriptions recorded.
- Uptake drivers include increased awareness, revised guidelines, and the drug's slide in the treatment of narcolepsy and hypersomnia.
Competitive Landscape
- Xyrem (sodium oxybate): Market leader with established patient base.
- Other options: Modafinil, armodafinil, stimulants, and off-label therapies.
- Xywav’s advantages include lower sodium content and suggested improved safety profile, encouraging prescriber switching.
Pricing Analysis
Manufacturer Price
- Wholesale Acquisition Cost (WAC): Approximately $70 per 5 mL vial (as of Q2 2023).
- Average weekly dose: 9-12 mL (based on patient weight, severity).
- Weekly cost estimate: $126 to $168 per patient.
Reimbursement and Net Price
- Average net price after discounts, rebates, and payor negotiations: $50-$60 per vial.
- Adjusted for typical treatment duration, annual costs range between $15,000 to $20,000 per patient.
Market Projections (2023-2028)
| Year |
Estimated Patients (US) |
Revenue (USD, millions) |
Key Drivers |
| 2023 |
40,000 |
600 |
Initial uptake, prescriber adaptation |
| 2024 |
50,000 |
750 |
Expanded prescriber awareness, formulary access |
| 2025 |
65,000 |
975 |
Broader insurance coverage, increased awareness |
| 2026 |
80,000 |
1,200 |
Market penetration, expanded indications |
| 2027 |
100,000 |
1,500 |
Steady growth, new product launches |
| 2028 |
120,000 |
1,800 |
Saturation, increased long-term adoption |
Note: These projections assume a gradual increase in market share from current levels, driven by hospital procurement, formulary inclusion, and prescriber education.
Key Market Factors
- Regulatory Environment: Ongoing collaborations with payers and FDA approvals for additional indications could expand market size.
- Pricing trends: Industry pressures on rebate systems and payor negotiations could further reduce net prices.
- Patent and exclusivity issues: Patent protections until at least 2030, with limited biosimilar or generic competition expected before then.
Risks and Challenges
- Generic entry: Although patent protections remain in place, patent challenges could impact pricing.
- Reimbursement changes: Revisions in CMS and private insurer policies could affect patient access and overall revenue.
- Off-label use: Potential expansion beyond approved indications could influence market size.
Key Takeaways
- NDC 72241-0038 (Xywav) entered a market with approximately 125,000 target patients in the US.
- Current WAC is about $70 per vial; average net price ranges from $50 to $60.
- Market projection for 2023-2028 indicates a compound annual growth rate (CAGR) of roughly 20%, driven by prescriber adoption and expanded indications.
- Revenue estimates reach approximately $1.8 billion by 2028, assuming steady market penetration.
- Risks include patent challenges and reimbursement policy shifts that could influence pricing and access.
FAQs
1. What is the primary therapeutic use of NDC 72241-0038 (Xywav)?
It treats narcolepsy with cataplexy and idiopathic hypersomnia.
2. How does its pricing compare to Xyrem?
Xywav’s WAC is similar to Xyrem’s, but due to lower sodium content, payers may favor it, influencing negotiated prices.
3. What factors could accelerate market penetration?
Increased prescriber familiarity, updated guidelines emphasizing safety profiles, and expanded insurance coverage.
4. Are there pending patent or exclusivity issues?
Yes. Patent protection extends until at least 2030, reducing near-term generic competition.
5. What are the main challenges for this drug’s market growth?
Potential patent litigation, reimbursement policy shifts, and competition from off-label therapies.
Sources:
[1] FDA. (2021). Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution. URL
[2] IQVIA. (2023). US prescription data. URL
[3] Jazz Pharmaceuticals. (2023). Annual Report. URL
[4] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies. URL
[5] MarketWatch. (2023). Pharmaceutical industry revenue projections. URL
